Saturday, April 25, 2015 11:52:24 AM
Could it possibly be the guy who said...
"Why is retired professor's work being touted when, if he did work on anything with NNVC "recently" the most recent would have been in 2013?"
The guy who said this is clearly implying that the PR was from a study done years ago. The PR clearly states that is was recent. The PR also states that it was done in the "lab of Dr. Rosenthal" not "by Dr. Rosenthal.
It also states he is now 'Professor Emeritus' which clearly states he is retired as that's what Professor Emeritus means. Professor Emeritus is still involved on consultation purposes as anyone would know that no one is going to walk away completely from a lifetime of work.
Dr. Rosenthal's comments were made after the study was done in the lab named after him which still and will always exist. He was consulted and made the comments that the cides were clearly preventing the breakout which is the main problem with humans having herpes.
At least 50 percent of the global population live with the virus in their nervous system. The breakouts affect over 1 billion people (shingles, cold sores, genital herpes). Chicken pox is the same virus and if anyone that is suffering from shingles (the recurring breakouts of the herpes/chicken pox virus) could stop the breakouts and ease their suffering they would be all over it like a hobo on a ham sandwich.
This market is producing over 900 Million dollars in revenue to the top three drugs which are only 2 percent effective. Should the continued studies show the 90 percent rate NNVC has achieved the market size would be much much larger. Very few are opting for the current drugs because they simply don't work.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM